In last trading session, KalVista Pharmaceuticals Inc (NASDAQ:KALV) saw 0.41 million shares changing hands with its beta currently measuring -0.02. Company’s recent per share price level of $11.93 trading at $0.27 or 2.32% at ring of the bell on the day assigns it a market valuation of $593.10M. That closing price of KALV’s stock is at a discount of -29.92% from its 52-week high price of $15.50 and is indicating a premium of 38.81% from its 52-week low price of $7.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.49 million shares which gives us an average trading volume of 612.68K if we extend that period to 3-months.
For KalVista Pharmaceuticals Inc (KALV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
KalVista Pharmaceuticals Inc (NASDAQ:KALV) trade information
Upright in the green during last session for gaining 2.32%, in the last five days KALV remained trading in the green while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $11.93 price level, adding 4.71% to its value on the day. KalVista Pharmaceuticals Inc’s shares saw a change of 40.85% in year-to-date performance and have moved 0.25% in past 5-day. KalVista Pharmaceuticals Inc (NASDAQ:KALV) showed a performance of 1.58% in past 30-days. Number of shares sold short was 5.86 million shares which calculate 8.82 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 20 to the stock, which implies a rise of 40.35% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would drop -67.64% in reaching the projected high whereas dropping to the targeted low would mean a loss of -67.64% for stock’s current value.
KalVista Pharmaceuticals Inc (KALV) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -20.06% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -3.28% while estimates for its earnings growth in next 5 years are of 21.51%.
KalVista Pharmaceuticals Inc (NASDAQ:KALV)’s Major holders
Insiders are in possession of 1.36% of company’s total shares while institution are holding 112.19 percent of that, with stock having share float percentage of 113.73%. Investors also watch the number of corporate investors in a company very closely, which is 112.19% institutions for KalVista Pharmaceuticals Inc that are currently holding shares of the company. VR ADVISER, LLC is the top institutional holder at KALV for having 6.25 million shares of worth $73.62 million. And as of 2024-06-30, it was holding 13.5179 of the company’s outstanding shares.
The second largest institutional holder is TANG CAPITAL MANAGEMENT LLC, which was holding about 4.22 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.1252 of outstanding shares, having a total worth of $49.7 million.
On the other hand, SMALLCAP WORLD FUND INC and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 3.18 shares of worth $37.91 million or 6.39% of the total outstanding shares. The later fund manager was in possession of 1.4 shares on Dec 31, 2024 , making its stake of worth around $16.68 million in the company or a holder of 2.81% of company’s stock.
